Author Archive | Raynovich Rod

Rayno Life Science Portfolio Racks-Up More Gains: REGN, RGDX, SRLS

go to site Who Does Not Know About the Bull Market in Biotech Stocks? The bull market in life science stocks gathered momentum today as the IBB rallied 2.34% (up 16.6% YTD) approaching its all time high of $122.45. At some point in time we need to have a correction as this rally is approaching 1999 ebullience. I […]

Continue Reading 0

Response Genetics Raises $7.5M at $1.50 with New CEO

buy Pregabalin in uk Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX)  announced today that it has entered purchase agreements with private investors including current holders to raise more than $7.8M with placement of 5.3M un-registered shares of common stock at a price […]

Continue Reading 0

Biopharma Market Re-Ignited by News and NASDAQ Strength

http://oceanadesigns.net/images/granite/breche-de-vandome/breche-de-vandome.jpg The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move the stock. Medivation has no revenue and […]

Continue Reading 0

Rayno Biopharmaceuticals Portfolio 2/09/09-1/27/12

Rayno Life Science Biopharmaceutical Picks Beat All Sector Averages Life Science Market  Hits 10 Year High Tracked by IBB ($115.51), and Up 46% Over 5 years Highlights of Rayno Biopharma Portfolio Biggest winners over 3 years were Alexion, Biogen, Micromet, Regeneron, Targacept and Viropharma. Targacept was at one time was a 20X return but is […]

Continue Reading 0

Rayno Life Science Portfolio: Another Buyout- MITI Goes for $1.16B

M&A Trend Picks Up Steam The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment  of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage  product candidates. The stock was $5 on November 25 ,2011. Micromet was added to the Rayno Life Science […]

Continue Reading 0

Roche Bid for Illumina (ILMN) Drives Biotech Sector to New Highs

M&A Theme Provides Underlying Bid to Market Roche Holding, the most diversified diagnostics and pharmaceutical Company with an aggressive leveraged strategy for the molecular basis of disease and personalized medicine has offered $5.7B for the leading Company in genetic sequencing and life science tools with revenues in the $1B range. The offer was $44.50 but […]

Continue Reading 0

“January Effect” Traders: Take Some Profits

If you followed our trades from November /December you made at least 20% so why push it? The Rayno Life Science Portfolio is down 0.75% today in a choppy  market. Our mid-cap biopharmaceutical index is down 0.87% but diagnostics and tools are  down only 0.3% as they were hit hard over the past 3 months. […]

Continue Reading 0

“January Effect” Rolls On with Biotech Stocks Up Over 1%, 9.3% MTD

Seems a Bit Frothy Large and mid-cap biopharmaceutical stocks continued to surge today with the bellwether ETF IBB ($114) hitting one year highs of $114.15 today. Many of our recent focus picks also continue to roll ahead: Astex (ASTX $2.18) up 4.8%, Gilead (GILD $47.40) up 2.4%,ImmunoGen (IMGN $12.75) up 3.3%, Seattle Genetics (SGEN $18) up […]

Continue Reading 0

Trends from the JPMorgan Healthcare Conference 2012

Healthcare: Broad Trends and Business Concepts for 2012 Last year we published an overview of trends for the 2011 JPMorgan Conference. Here is a very brief review from this year’s Conference: The lagging Life Science Tools sector was ignited by new sequencing and genetic analysis products from Life Technologies (LIFE) and Illumina (ILMN). NIH and […]

Continue Reading 0

“January Effect” Rally: A Cliched Trade That Really Works

You read about it every year, and always there are skeptics, but in Q4 2011 to Q 2012 the “January effect ” rally for small cap and life science stocks were big winners. Why does this happen? Not so important just that it does happen. Here are our December focus picks (see earlier posts):   […]

Continue Reading 0